Publicaciones en colaboración con investigadores/as de Universidad de Oviedo (15)

2024

  1. Functioning in schizophrenia: Recommendations of an expert panel

    Schizophrenia Research, Vol. 270, pp. 317-322

2019

  1. CIBERSAM: Ten years of collaborative translational research in mental disorders

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 1-8

  2. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 2, pp. 92-105

2017

  1. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial

    BMC Psychiatry, Vol. 17, Núm. 1

  2. Eficacia, eficiencia y efectividad en el tratamiento multidimensional de la esquizofrenia: proyecto Rethinking

    Revista de Psiquiatria y Salud Mental, Vol. 10, Núm. 1, pp. 4-20

2007

  1. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms

    European Neuropsychopharmacology, Vol. 17, Núm. 11, pp. 725-734

  2. Safety and tolerability of olanzapine versus risperidone: A one-year randomized study in outpatients with schizophrenia with prominent negative symptoms

    Actas Espanolas de Psiquiatria, Vol. 35, Núm. 2, pp. 105-114

2006

  1. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia

    Journal of Clinical Psychopharmacology, Vol. 26, Núm. 3, pp. 238-249

  2. Análisis de los patrones de prescripción de antipsicóticos en psiquiatría

    Actas Espanolas de Psiquiatria, Vol. 34, Núm. 5, pp. 323-329

  3. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 30, Núm. 8, pp. 1515-1522

  4. Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 Year follow-up naturalistic study

    Actas Espanolas de Psiquiatria, Vol. 34, Núm. 1, pp. 7-15

  5. Subjective perception of cognitive deficit in psychotic patients

    Journal of Nervous and Mental Disease, Vol. 194, Núm. 1, pp. 58-60

2005

  1. The Self-Assessment Anhedonia Scale (SAAS)

    Neurology Psychiatry and Brain Research, Vol. 12, Núm. 3, pp. 121-133

  2. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 972-982

2003

  1. Escala GEOPTE de cognición social para la psicosis: GEOPTE (Grupo Español para la Optimización y Tratamiento de la Esquizofrenia)

    Actas Espanolas de Psiquiatria, Vol. 31, Núm. 3, pp. 120-128